Moderna's melanoma vaccine succeeds in major trial. So why did its stock plunge?

ynet (אנגלית) תרבות

Moderna and Merck's personalized mRNA vaccine raised two-year recurrence-free survival to 82.2%, from 70% with Keytruda alone; despite the Phase 3 success, Moderna shares plunged 18%, overall survival remains unproven and US approval is…